These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

755 related items for PubMed ID: 21975559

  • 1. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [Abstract] [Full Text] [Related]

  • 5. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [Abstract] [Full Text] [Related]

  • 6. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC, Tong KH, To CH, Siu YP, Ma KM.
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [Abstract] [Full Text] [Related]

  • 7. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 8. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
    Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H.
    Breast Cancer Res; 2010 Feb; 12(2):R24. PubMed ID: 20398352
    [Abstract] [Full Text] [Related]

  • 9. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [Abstract] [Full Text] [Related]

  • 11. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
    Kriel MH, Tobias JH, Creed TJ, Lockett M, Linehan J, Bell A, Przemioslo R, Smithson JE, Brooklyn TN, Fraser WD, Probert CS.
    Osteoporos Int; 2010 Mar; 21(3):507-13. PubMed ID: 19484170
    [Abstract] [Full Text] [Related]

  • 12. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M, Kyvernitakis I, Albert US, Baier-Ebert M, Hadji P.
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [Abstract] [Full Text] [Related]

  • 13. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R.
    Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
    [Abstract] [Full Text] [Related]

  • 14. Effect of single dose intravenous zoledronic acid on bone mineral density in post-menopausal osteoporosis of Bangladeshi women.
    Hossain M, Chowdhury IH, Emran MA, Habib AH, Asaduzzamnan AK, Alam M, Ferdous C.
    Bangladesh Med Res Counc Bull; 2010 Dec; 36(3):74-7. PubMed ID: 21548542
    [Abstract] [Full Text] [Related]

  • 15. Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
    Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD.
    Osteoporos Int; 2009 Nov; 20(11):1895-902. PubMed ID: 19296144
    [Abstract] [Full Text] [Related]

  • 16. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 17. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 18. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
    Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK.
    J Bone Miner Res; 2013 Jun; 28(6):1355-68. PubMed ID: 23322362
    [Abstract] [Full Text] [Related]

  • 20. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.